巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Arcus Biosciences

    RCUS
    19.010
    0.090
    0.48%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Arcus Biosciences - 延遲價格・最後更新於 23/05 2:22
    最高位
    19.540
    最低位
    18.930
    開市價
    --
    前收市價
    18.920
    成交量(千)
    3.96
    成交額(百萬)
    0.65
    買入
    19.010
    賣出
    19.170
    每手股數
    --
    市值(百萬)
    1,363.37
    市盈率
    22.900
    息率
    --
    差價
    --
    52週高低
    49.100 - 16.740
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Arcus Biosciences
    證券代碼
    RCUS.US
    所屬板塊
    Biotechnology
    公司業務
    Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
    發行量
    71061867
    公司總部
    3928 Point Eden Way
    公司網址
    https://www.arcusbio.com
    公司電郵
    investorinfo@arcusbio.com
    公司電話
    +1 510 694-6200
    暫無內容

    關於

    Arcus Biosciences(RCUS.US)所屬的行業板塊為Biotechnology。
    Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
    詳細公司背景可參考: https://www.arcusbio.com